PMID- 17493356
OWN - NLM
STAT- MEDLINE
DCOM- 20071030
LR  - 20161018
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 15
IP  - 2
DP  - 2007 Apr
TI  - [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on 
      expression of nuclear transcription factor-kappaB in childhood acute 
      lymphoblastic leukemia and its significance].
PG  - 399-403
AB  - In order to investigate the effect of N-tosyl-L-phenylalnylchloromethyl ketone 
      (TPCK) and dexamethasone (Dex) on expression of nuclear transcription 
      factor-kappaB (NF-kappaB) in childhood acute lymphoblastic leukemia (ALL) and its 
      significance, so as to provide the experimental basis for corresponding clinical 
      treatment of ALL, in which NF-kappaB is taken as a target. The 
      biotin-streptavidin method was used to detect the expression of NF-kappaB P65 
      protein and the effects of TPCK and Dex at clinically relevant dosage on activity 
      of NF-kappaB P65 protein in 20 childhood ALL patients. The results indicated that 
      the expression of NF-kappaB P65 protein was strongly diminished and reached to 
      negative level at 2 hours by treatment with 40 micromol/L TPCK, the positive 
      expression of NF-kappaB P65 protein was (2.5 +/- 1.6)%. TPCK had a time-dependent 
      inhibitory effect on ALL cells cultured in vitro. The expression of NF-kappaB P65 
      protein in ALL cells was strongly inhibited by clinically relevant concentration 
      of dexamethasone 5.0 microg/ml for 24 hours in vitro. The positive expression was 
      (25.0 +/- 3.0)%, there was significant difference, as compared with untreated ALL 
      cells (T=55, P<0.01). It is concluded that TPCK and Dex can inhibit NF-kappaB 
      activity. Inhibition of NF-kappaB activity may be one of the effect mechanism of 
      dexamethasone on ALL cells. Inhibition of NF-kappaB conduction pathway may have a 
      significant value in childhood ALL treatment.
FAU - An, Qig
AU  - An Q
AD  - Department of Hematology, Xuzhou Children Hospital, Xuzhou 221006, China.
FAU - Xue, Tian-Yang
AU  - Xue TY
FAU - Xu, Wei
AU  - Xu W
FAU - Gao, Ji-Zhao
AU  - Gao JZ
FAU - Wu, Yi
AU  - Wu Y
FAU - Xu, Chun-Pin
AU  - Xu CP
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - 0 (NF-kappa B)
RN  - 0 (Protein Synthesis Inhibitors)
RN  - 402-71-1 (Tosylphenylalanyl Chloromethyl Ketone)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Bone Marrow Cells/pathology
MH  - Cells, Cultured
MH  - Child
MH  - Child, Preschool
MH  - Dexamethasone/*pharmacology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Leukocytes, Mononuclear/pathology
MH  - Male
MH  - NF-kappa B/*biosynthesis/genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*metabolism/pathology
MH  - Protein Synthesis Inhibitors/pharmacology
MH  - Tosylphenylalanyl Chloromethyl Ketone/*pharmacology
MH  - Tumor Cells, Cultured
EDAT- 2007/05/12 09:00
MHDA- 2007/10/31 09:00
CRDT- 2007/05/12 09:00
PHST- 2007/05/12 09:00 [pubmed]
PHST- 2007/10/31 09:00 [medline]
PHST- 2007/05/12 09:00 [entrez]
AID - 1009-2137(2007)02-0399-05 [pii]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Apr;15(2):399-403.